Various preclinical models have been developed to clarify the pathophysiology of prostate
cancer (PCa). Traditional PCa cell lines from clinical metastatic lesions, as exemplified by …

Metastasis to bone is common in lung, kidney, breast and prostate cancers. However,
prostate cancer is unique in that bone is often the only clinically detectable site of …

TMPRSS2 is an androgen-regulated cell-surface serine protease expressed predominantly
in prostate epithelium. TMPRSS2 is expressed highly in localized high-grade prostate …

FOXA1 functions as a pioneer transcription factor by facilitating the access to chromatin for
steroid hormone receptors, such as androgen receptor and estrogen receptor,,–, but …

Progression of prostate cancer following castration is associated with increased androgen
receptor (AR) expression and signaling despite AR blockade. Recent studies suggest that …

Therapy for advanced prostate cancer centers on suppressing systemic androgens and
blocking activation of the androgen receptor (AR). Despite anorchid serum androgen levels …

Purpose: Abiraterone is a potent inhibitor of the steroidogenic enzyme CYP17A1 and
suppresses tumor growth in patients with castration-resistant prostate cancer (CRPC). The …

The standard systemic treatment for prostate cancer (PCa) is androgen ablation, which
causes tumor regression by inhibiting activity of the androgen receptor (AR). Invariably, PCa …

Androgen deprivation is currently a standard-of-care, first-line therapy for prostate cancer in
the United States. Although this regimen effectively regresses androgen-dependent disease …

Purpose: We describe the preclinical pharmacology and antitumor activity of GDC-0068, a
novel highly selective ATP-competitive pan-Akt inhibitor currently in clinical trials for the …